Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma-Reference-Cited by-同舟云学术

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma

Published:2019-09-26 Issue:11 Volume:33 Page:2762-2766
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Wang Michael^ORCID,Rule Simon^ORCID,Zinzani Pier Luigi,Goy Andre,Casasnovas Olivier,Smith Stephen D.,Damaj Gandhi,Doorduijn Jeanette K.,Lamy Thierry,Morschhauser Franck,Panizo Carlos,Shah Bijal,Davies Andrew,Eek Richard,Dupuis Jehan,Jacobsen Eric,Kater Arnon P.,Le Gouill Steven,Oberic Lucie,Robak Tadeusz,Jain Preetesh,Frigault Melanie M.,Izumi Raquel,Nguyen Dorothy,Patel Priti,Yin Ming,Długosz-Danecka Monika

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0575-9.pdf

Reference6 articles.

1. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 2018;391:659–67.

2. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507–16.

3. Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med 2018;378:1211–23.

4. Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 2016;387:770–8.

5. Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, et al. Acalabrutinib (ACP-196): a covalent Bruton Tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile. J Pharm Exp Ther 2017;363:240–52.

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas;Blood Advances;2024-09-10

2. Dismantling relapsed/refractory mantle cell lymphoma;Blood Reviews;2024-09

3. Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma;Expert Review of Hematology;2024-08-08

4. Mantle Cell Lymphoma Under the Scope of Personalized Medicine: Perspective and Directions;Clinical Lymphoma Myeloma and Leukemia;2024-07

5. Carfilzomib, lenalidomide, dexamethasone (KRD) in BTKi relapsed or refractory mantle cell lymphoma: A phase II study from Fondazione Italiana Linfomi;British Journal of Haematology;2024-06-28